When tumors reached 1 mm in diameter (7 to 10 d post-implantation), mice were treated daily with phosphate-buffered saline (PBS;control) or losartan (Selleckchem) daily at 60 mg/kg until study endpoint. After 1 wk of losartan pretreatment, mice were treated with IgG (control) or anti-PD1 (BioxCell, RMP1-14) every 3 d for three doses at 200 μg/mouse. SOC mice received concurrently with losartan: 5 d of consecutive radiotherapy (2 Gy/d) and 10 d of consecutive chemotherapy (temozolomide, Selleckchem) at 25 mg/kg. All drugs were injected i.p. For flow cytometry, scRNASeq, intravital imaging, histology, and edema measurements, mice were imaged/sacrificed after the third dose of anti-PD1 and/or 2 wk of losartan treatment.
Losartan
Losartan is a laboratory reagent used in research and development applications. It functions as an angiotensin II receptor antagonist, which is a class of compounds that block the action of the hormone angiotensin II. This activity is useful for various biological and pharmacological studies.
Lab products found in correlation
12 protocols using losartan
Brain Tumor Implantation and Treatment
When tumors reached 1 mm in diameter (7 to 10 d post-implantation), mice were treated daily with phosphate-buffered saline (PBS;control) or losartan (Selleckchem) daily at 60 mg/kg until study endpoint. After 1 wk of losartan pretreatment, mice were treated with IgG (control) or anti-PD1 (BioxCell, RMP1-14) every 3 d for three doses at 200 μg/mouse. SOC mice received concurrently with losartan: 5 d of consecutive radiotherapy (2 Gy/d) and 10 d of consecutive chemotherapy (temozolomide, Selleckchem) at 25 mg/kg. All drugs were injected i.p. For flow cytometry, scRNASeq, intravital imaging, histology, and edema measurements, mice were imaged/sacrificed after the third dose of anti-PD1 and/or 2 wk of losartan treatment.
TGF-β1 Signaling Pathway Modulation
Angiotensin II Signaling Inhibition in NK/T-cell Lymphoma
Vascular Tension Modulation Assay
Antifibrotic Pathway Modulation Assay
Angiotensin II Signaling Pathway
Cardiac Myofibroblast Differentiation on Hydrogels
In addition, to explore the role of AT1R in cardiac myofibroblast differentiation, losartan (AT1R inhibitor) (Selleckchem, Houston, USA) at 10−7 M was given to cardiac fibroblasts cultured on PA hydrogels on day 4. The treatment was lasted for 1 day. The cells were then subjected to cardiac myofibroblast differentiation assessment.
Neonatal Rat Cardiomyocyte and Fibroblast Isolation
Alcohol-Induced Cardiac Injury Mitigation
Chemical Compound Procurement Protocol
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!